CJC-1295 + Ipamorelin monograph

CJC-1295 + Ipamorelin

Overview

CJC-1295 and ipamorelin are both research peptides used together in bodybuilding circles to stimulate pulsatile growth hormone release, usually with the goal of better recovery, sleep, or body-composition changes. The combination is not an FDA-approved medicine for bodybuilding, and the human evidence for performance use is thin and largely investigational. Sports-medicine review literature describes growth hormone axis secretagogues such as CJC-1295 and ipamorelin as experimental, with uncertain safety, product-quality concerns, and antidoping restrictions (PubMed).

Pharmacokinetics & Mechanism

• Class: Investigational growth hormone secretagogue peptide combination
• Mechanism of action: CJC-1295 is a growth hormone-releasing hormone receptor agonist/analogue that stimulates endogenous GH secretion from the pituitary; the DAC (drug affinity complex) version is long-acting because of albumin binding, while the non-DAC/“no DAC” version is short-acting. Ipamorelin is a selective growth hormone secretagogue receptor (GHSR-1a) agonist that promotes pulsatile GH release with relatively minimal cortisol/prolactin signal compared with older secretagogues. Used together, they aim to amplify endogenous GH pulses rather than replace GH directly; however, performance-oriented use is not well supported by robust human outcomes data (PubMed).
• Target(s): Primary targets: GHRH receptor for CJC-1295; ghrelin/growth hormone secretagogue receptor 1a (GHSR-1a) for ipamorelin. Downstream pathway: pituitary somatotroph activation with increased GH secretion and secondary IGF-1 signaling via the GH/IGF-1 axis (NCBI Gene GH1, PubMed).
• Route(s) of administration: Subcutaneous injection is the standard route described in bodybuilding/community use and in peptide research discussions. Not well established for oral or intranasal use; those routes are not standard for these compounds (PubMed).
• Onset: Acute GH pulse effects are expected within about 15-60 minutes after subcutaneous administration based on the intended physiology of GH secretagogues, but precise human onset data for the CJC-1295 + ipamorelin combination are not well established. Community use commonly times injections before bed or away from meals to align with endogenous GH pulses; that timing is anecdotal rather than proven clinical protocol (Reddit, Reddit).
• Half-life: CJC-1295 depends on the variant: the DAC version is long-acting, with published pharmacokinetic descriptions commonly summarized as roughly 5-8 days or a terminal half-life measured in days; the non-DAC version is short-acting and is often described in community discussion as lasting only a short time, but a precise human half-life for the no-DAC version is not well established in the sources retrieved. Ipamorelin is generally described as short-acting with a brief plasma half-life in the minutes range, but the exact human half-life varies across secondary sources and is not consistently established in open authoritative monographs available here. Because of source conflict and limited accessible primary data, treat both as short-to-very-short acting for pulse-stimulation purposes, except CJC-1295 DAC which is extended-duration (PubMed).
• Metabolism / clearance: Not well established in humans for the combination. CJC-1295 DAC is designed for prolonged exposure via albumin binding and eventual proteolytic peptide breakdown; ipamorelin, as a peptide, is expected to undergo enzymatic proteolysis and nonspecific peptide clearance. No authoritative human metabolism/clearance monograph specific to the combination was found in the retrieved sources.